| (19) |
 |
|
(11) |
EP 1 512 413 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
23.09.2009 Bulletin 2009/39 |
| (43) |
Date of publication A2: |
|
09.03.2005 Bulletin 2005/10 |
| (22) |
Date of filing: 14.01.2002 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
| (30) |
Priority: |
16.01.2001 US 262402 P
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
02703127.7 / 1353693 |
| (71) |
Applicant: GLAXO GROUP LIMITED |
|
Greenford, Middlesex UB6 ONN (GB) |
|
| (72) |
Inventors: |
|
- Lackey, Karen Elizabeth
Research Triangle Park
NC 27709 (US)
- Spector, Neil
Research Triangle Park
NC 27709 (US)
- Wood, Edgar Raymond, III
Research Triangle Park
NC 27709 (US)
- Xia, Wenle
Research Triangle Park
NC 27709 (US)
|
| (74) |
Representative: Reed, Michael Antony et al |
|
GlaxoSmithKline
Corporate Intellectual Property (CN9.25.1)
980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB) |
|
| |
|
| (54) |
Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic
agent for the treatment of cancer |
(57) A method of treating cancer is described including administration of a 4-quinazolineamine
and at least one other anti-neoplastic agent as well as a pharmaceutical combination
including the 4-quinazolineamines.